文献速递妇科

在低风险人群中验证ADNEX模型和IOTA两步策略并评估附件肿块随访期间并发症风险

Validation of ADNEX and IOTA two-step strategy and estimation of risk of complications during follow-up of adnexal masses in low-risk population.
PubMed 文献 · Ultrasound Obstet Gynecol · 2024-08-16

本研究在西班牙巴塞罗那一家私立中心的前瞻性观察性IOTA5研究数据中,回顾性评估ADNEX模型(不含CA125)和IOTA两步策略对低风险门诊附件肿块良恶性鉴别的能力,并随访超声形态良性肿块保守管理的并发症风险。共纳入2039例新发肿块患者,ADNEX模型AUC为0.95(95% CI 0.89-0.98),两步策略AUC为0.94(95% CI 0.88-0.97);1472例超声判断良性并随访的患者中,5年累积自发消退率66%(95% CI 63-69%),扭转0%(95% CI 0-0.2%),囊肿破裂0.1%(95% CI <0.1-0.4%),交界性肿瘤0.2%(95% CI 0.1-0.6%),浸润性恶性肿瘤0.2%(95% CI 0.1-0.6%)。

要点

  • ADNEX模型(不含CA125)鉴别低风险人群附件肿块良恶性的AUC为0.95(95% CI 0.89-0.98)。
  • IOTA两步策略的AUC为0.94(95% CI 0.88-0.97),在恶性风险阈值<3%时临床净获益优于ADNEX模型。
  • 超声形态良性并保守随访的肿块5年累积扭转风险0%、囊肿破裂风险0.1%、恶性肿瘤风险0.2%。

核心结论

  • ADNEX模型和IOTA两步策略在低风险人群中区分附件肿块良恶性表现良好。
  • 在该人群中,超声表现良性的肿块进行保守管理是安全的。

研究设计与样本

  • 单中心研究,在西班牙巴塞罗那Hospital Universitari Dexeus进行,使用正在进行的IOTA5前瞻性观察性研究的 interim 数据。
  • 纳入2012年6月至2016年9月在一家提供妇科癌症筛查的私立中心连续检出的附件肿块患者,随访至2020年2月。
  • 共招募2654例患者,应用排除标准后2039例新发肿块患者纳入模型验证。
  • 肿瘤分类基于组织学(若患者接受手术)或12个月(范围10-14个月)临床和超声随访结局;结局不确定时采用多重插补。
  • 回顾性评估ADNEX模型(不含CA125)和IOTA两步策略鉴别良恶性的能力,评估指标包括区分度(AUC)、校准、分类(敏感性和特异性)和临床效用(净获益)。

主要发现

  • 2039例肿块中,1684例(83%)为良性,49例(2%)为恶性,306例(15%)结局不确定并插补。
  • ADNEX模型(不含CA125)的AUC为0.95(95% CI 0.89-0.98),IOTA两步策略的AUC为0.94(95% CI 0.88-0.97)。
  • 由于恶性肿瘤数量少导致置信区间非常宽,校准性能无法有意义地解读。
  • 在恶性风险阈值<3%时,IOTA两步策略的临床效用优于ADNEX模型。
  • 1472例(72%)患者经有经验超声医师模式识别判断为良性并接受临床和超声随访,5年累积发生率:自发消退66%(95% CI 63-69%),扭转0%(95% CI 0-0.2%),囊肿破裂0.1%(95% CI <0.1-0.4%),交界性肿瘤0.2%(95% CI 0.1-0.6%),浸润性恶性肿瘤0.2%(95% CI 0.1-0.6%)。

临床怎么用

  • 作者结论认为,ADNEX模型和IOTA两步策略在低风险人群中区分附件肿块良恶性表现良好。
  • 作者结论认为,在该人群中超声表现良性的肿块保守管理是安全的。

局限性

  • 校准性能无法有意义地解读,因为恶性肿瘤数量少导致置信区间非常宽。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To evaluate the ability of the Assessment of Different NEoplasias in the adneXa (ADNEX) model and the International Ovarian Tumour Analysis (IOTA) two-step strategy to predict malignancy in adnexal masses detected in an outpatient low-risk setting, and to estimate the risk of complications in masses with benign ultrasound morphology managed using clinical and ultrasound follow-up. METHODS: This single-center study was performed at Hospital Universitari Dexeus, Barcelona, Spain, using interim data from the ongoing prospective observational IOTA Phase-5 (IOTA5) study. The primary aim of the IOTA5 study is to describe the cumulative incidence of complications during follow-up of adnexal masses classified as benign on ultrasound examination. Consecutive patients with an adnexal mass detected between June 2012 and September 2016 in a private center offering screening for gynecological cancer were included and followed up until February 2020. Tumors were classified as benign or malignant based on histology (if patients underwent surgery) or the outcome of clinical and ultrasound follow-up at 12 (range, 10-14) months. Multiple imputation was used when outcomes were uncertain. The ability of the ADNEX model without CA125 and of the IOTA two-step strategy to distinguish benign from malignant masses was evaluated retrospectively using the prospectively collected data. We assessed performance with regard to discrimination (area under the receiver-operating-characteristics curve (AUC)), calibration, classification (sensitivity and specificity) and clinical utility (Net Benefit). In the group of patients with a mass judged to be benign who were selected for conservative management, we evaluated the occurrence of spontaneous resolution or any mass complication during the first 5 years of follow-up by assessing the cumulative incidence of malignancy, torsion, cyst rupture and minor mass complications (inflammation, infection or adhesions) and the time to occurrence of an event. RESULTS: A total of 2654 patients were recruited to the study. After application of exclusion criteria, 2039 patients with a newly detected mass were included for the model validation. Of those, 1684 (83%) masses were benign, 49 (2%) masses were malignant and, for 306 (15%) masses, the outcome was uncertain and therefore imputed. The AUC was 0.95 (95% CI, 0.89-0.98) for ADNEX without CA125 and 0.94 (95% CI, 0.88-0.97) for the two-step strategy. Calibration performance could not be meaningfully interpreted because the small number of malignancies resulted in very wide confidence intervals. The two-step strategy had better clinical utility than did the ADNEX model at malignancy risk thresholds < 3%. There were 1472 (72%) patients whose mass was judged to be benign based on pattern recognition by an experienced ultrasound examiner and were managed with clinical and ultrasound follow-up. In this group, the 5-year cumulative incidence was 66% (95% CI, 63-69%) for spontaneous resolution of the mass, 0% (95% CI, 0-0.2%) for torsion, 0.1% (95% CI, < 0.1-0.4%) for cyst rupture, 0.2% (95% CI, 0.1-0.6%) for a borderline tumor and 0.2% (95% CI, 0.1-0.6%) for invasive malignancy. CONCLUSIONS: The ADNEX model and IOTA two-step strategy performed well to distinguish benign from malignant adnexal masses detected in a low-risk population. Conservative management is safe for masses with a benign ultrasound appearance in this population. © 2024 International Society of Ultrasound in Obstetrics and Gynecology.

来源:Ultrasound Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Pascual MA, Vancraeynest L, Timmerman S, et al. Validation of ADNEX and IOTA two-step strategy and estimation of risk of complications during follow-up of adnexal masses in low-risk population. Ultrasound Obstet Gynecol. 2024. PMID: 38477179. doi:10.1002/uog.27642

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。